Key Metrics
Factor Lens
Seasonal Performance
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. The Company's global headquarters is in… Wilmington, Delaware, with additional offices in Morges (Switzerland), Tokyo (Japan), Montreal (Canada), and across Europe. Incyte is focused in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). In Hematology, the Company markets JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; ICLUSIG (ponatinib) for chronic and acute myeloid leukemia; MONJUVI/MINJUVI (tafasitamab) for diffuse large B-cell lymphoma and follicular lymphoma; and NIKTIMVO (axatilimab) for chronic graft-versus-host disease. In Oncology, the Company markets ZYNYZ (retifanlimab) and PEMAZYRE (pemigatinib). In IAI, the Company markets OPZELURA (ruxolitinib cream) for atopic dermatitis and vitiligo. The Company operates through its own specialty sales force and through collaboration agreements with partners including Novartis for ruxolitinib outside the United States and Eli Lilly for certain development programs. The Company has a clinical pipeline with multiple programs in hematology, oncology and immunology, including development-stage candidates in GVHD, myeloproliferative neoplasms, B-cell malignancies, solid tumors, and inflammatory skin diseases.
- Name
- Incyte Corporation
- Sector
- Industrials
- Industry
- Industrials
- CEO
- William J. Meury · Chief Executive Officer
- Employees
- 3,200 as of 2025-12-31
- IPO Date
- 2019-01-02
- Phone
- (302) 498-6700
- Address
- 1801 Augustine Cut-Off, Wilmington, DE 19803
- Website
- https://www.incyte.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Jean-Jacques Bienaimé | Independent Director | — |
| Julian C. Baker | Chair of the Board | — |
| Richard Hoffman | Secretary | — |
| Hervé Hoppenot | President and Former Chief Executive Officer | — |
| William J. Meury | Chief Executive Officer | — |
Latest News
- 2026-04-21
- 2026-04-21
- 2026-04-21
- 2026-04-20
- 2026-04-20
-
2026-04-18
KBC Group NV Sells 157,700 Shares of Incyte Corporation $INCY defenseworld.net
- 2026-04-08
- 2026-04-01